Periacetabular Osteotomy With and Without Arthroscopic Management of Central Compartment Pathology

NCT03481010 · tracked via the Priya Life Science Canada tracker

Sponsor

Ottawa Hospital Research Institute

Phase

Not applicable

Started

2018-04-04

Last updated

2025-12-30

Condition(s) studied

Hip Dysplasia

Investigational drug(s) / intervention(s)

PAO with hip arthroscopyPAO without hip arthroscopy

PAO with hip arthroscopy: Participants who are randomized to the Scope-PAO group will receive central compartment hip arthroscopy in addition to the PAO.

PAO without hip arthroscopy: Participants who are randomized to the "PAO-only" group will receive a Bernese Periacetabular Osteotomy (PAO) for treatment of hip dysplasia.

Study summary

At present, it is not clear whether performing a hip arthroscopy at the same time as a PAO improves patient outcomes after surgery compared to a PAO alone.

This research project will randomize patients to receive either a PAO alone, or a PAO and a hip arthroscopy at the same time.

Eligibility

Sex

ALL

Min age

16 Years

Max age

50 Years

Healthy volunteers

Inclusion Criteria: * Skeletally mature patient undergoing Bernese periacetabular osteotomy for symptomatic acetabular dysplasia/hip instability * Pre-Operative MRI at 3T and/or gadolinium MR arthrogram * Age, 16-50 years old * Patient capable of giving informed consent Exclusion Criteria: * Prior hip/pelvis surgery of any kind on the surgical side * Prior hip arthroplasty surgery on either side * Radiographic evidence of arthritis (i.e. Tönnis grade =2) * Known connective tissue disorder (e.g. Ehlers-Danlos Syndrome, etc.) * Known neuromuscular disorder (e.g. Cerebral Palsy, Spina bifida, etc.) * Known skeletal dysplasia (e.g. Achondroplasia, Multiple Epiphyseal Dysplasia, etc.) * Cognitive impairment that prevents accurate completion of patient-reported outcome questionnaires. * Patient unable/unwilling to complete all required follow-up visits * Concurrent proximal femoral osteotomy and/or surgical hip dislocation

Primary outcome measure(s)

iHOT-33 — 24 months
Patient-reported quality of life will be the primary outcome used for comparison between the two treatment groups as measured by the International Hip Outcome Tool (iHOT-33). The iHOT-33 is a validated, self-administered quality of life assessment tool for young, active patients with hip symptoms.

Trial sites (7)

Facility	City	Region	Status
Northwestern University	Chicago	Illinois	Recruiting
William Beaumont Hospital	Royal Oak	Michigan	Recruiting
The Washington University	St Louis	Missouri	Recruiting
Hospital for Special Surgery	New York	New York	Recruiting
Children's Hospital of Eastern Ontario	Ottawa	Ontario	Recruiting
Ottawa Hospital Research Institute	Ottawa	Ontario	Recruiting
CHU de Québec - Université Laval	Québec	Canada	Recruiting

More Ottawa Hospital Research Institute trials in Canada

THERApeutic Outcomes Related to Gut microBIOME in Glioblastoma (GBM) Patients Receiving Chemo-radiation (THERABIOME-GBM) Recruiting

Measured vs Navigated Techniques in Total Hip Arthroplasty Active, not recruiting

The PROAKTIVE Trial Starting soon

Mesenchymal Stromal Cell Therapy to Prevent Bronchopulmonary Dysplasia in Extreme Preterm Infants Starting soon

Umbilical Mesenchymal Stromal Cells as Cellular Immunotherapy for Septic Shock Recruiting

Other trials for the same condition

Developmental Dysplasia of the Hip: Observation vs. Bracing Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03481010 on ClinicalTrials.gov ↗ ← All trials in Canada